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Summary: A common methodology is reported for the determination of five major anticonvulsants (carbam-
azepine, ethosuximide, phenobarbital, phenytoin, primidone) and their active metabolites (carbamazepine-
10,11-epoxide, phenylethylmalonamide) in 30 of plasma.
After a single step of deproteinisation and extraction with acetonitrile, leading to an almost complete recovery
of all the analytes, 5 is injected on a reversed-phase column (Lichrosorb RP-18,5 ). The anticonvulsants
are eluted isocratically at a column temperature of 50 °C with a mobile phase consisting of acetonitrile/phos-
phate buffer pH 6.9 (40/60 by vol), and monitored at 208 nm. Quantitäten, using peak height or peak area, is
based on the ratio of analyte to internal Standard (allylisobutylbarbital) referenced to a serum-based multiple
drug Standard.
The composition and pH of the mobile phase, temperature of the column, choice of wavelength of detection
and size of the column material äre cruäal for the optimal Separation of these five drugs and their two active
metabolites in a Chromatographie time of only 12 min, without sacrificing high sensitivity and column life.
Gleichzeitige Bestimmung von Carbamazepin, Carbamazepin-10,11-epoxid, Ethosuximid, Phenobarbital,
Phenytoin, Primidon und Phenylethylmalonamid im Plasma durch Hochleistungsflüssigchromatographie
Zusammenfassung: Eine gerneinsame Methodologie für die Bestimmung der fünf wichtigsten Antikonvulsiva
(Carbamazepin, Ethosuximid, Phenobarbital, Phenytoin, Primidon) und ihrer aktiven Metabolite (Carbam-
azepin-10,ll-epoxid, Phenyethylmalonamid) in 30 Plasma wird beschrieben.
Nach Enteiweißung und Extraktion mit Acetonitril mit nahezu vollständiger Wiederfindung alle Analyte
werden 5 in eine „reversed phase"-Säüle (Lichrosorb RP-18, 5 ) injiziert. Die Antikonvulsiva werden
isokratisch bei einer Säulentemperatur von 50 °C mit Acetonitril/Phosphatpuffer pH 6,9 (Volumina,
40 + 60) eluiert und durch UV-Absorption bei 208 nm nachgewiesen.
Die quantitative Auswertung über Peak^Höhe und -Fläche beruht auf dem Verhältnis von Analyt zu innerem
Standard (Allylisobütylbarbitai), bezogen auf einen Viel-Drogen-Standard auf Serumbasis.
-Zusammensetzung und pH der mobilen Phase, Säulentemperatur, Wahl der Wellenlänge für den Nachweis
und Größe des Säulenmaterials sind 'für eine optimale Trennung der fünf Pharmaka und ihrer beiden aktiven
Metabolite bei einer Chromatographiedauer von nur 12 Minuten, ohne hohe Empfindlichkeit und Lebens-
dauer der Säule zu schmälern, von entscheidender Bedeutung.
methods suitable for large clinical populations. Ra-
imroducnon dio-immuno-assay, enzyme-immuno-assay, spec-
Since plasma concentrations of anticonvulsant trometry, gas-liquid-(GLC) and high-performance
agents show an accurate correlation with treatment liquid chromatography (HPLC) are used for this
efficacy, there is increasing interest in analytical purpose.
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Usually several components in a mixture must be an-
alysed. Immunological methods are less convenient
because separate analyses must be performed for
each drug, and cross-reactivity may also occur.
Chromatographie methods guarantee greater selec-
tivity and they have the advantage of rapid and sim-
ple Operation. A preliminary extraction of relatively
large quantities of biological material is inevitable
when the GLC method is used, which pleads in fa-
vour of HPLC methods.
Several HPLC methods have recently been reported
for the analysis of anticonvulsant drugs, applied
either to the assay of one specific anticonvulsant
(1-4), or to the simultaneous determination of sev-
eral anticonvulsants (5—11).
In an attempt to select a convenient method for the
therapeutic monitoring in plasma of mixtures of the
common anticonvulsants, ethosuximide, carbam-
azepine, phenobarbital, phenytoin, primidone and
their active metabolites (phenylethylmalonamide,
carbamäzepine-10,ll-epoxide), we have evaluated
several high-performance liquid Chromatographie
methods in our daily routine during a period of three
years. In our hands, various recently developed
procedures (6, 9, 11) are appropriate, but we pro-
pose several modifications with emphasis on simul-
taneous determination of active metabolites, easy
Operation, short Chromatographie time, high sensi-
tivity, long column life, and low cost.
Materials and Methods
Appara tus
We used a high performance liquid Chromatographie System (Wa-
ters Associates, Milford, M A 01757, U.S. A.), consisting of a
Model 45 solvent-delivery System, a Model 450 variable wave-
length ultraviolet absorbance detector, a Model (CV-6UHPa-
N 60 7000 psi manual sample injection Valve (Valco Instruments
Company, Houston, TX 77024, U.S.A.). The column was a
300 mm x 4.6 mm i. d. Li-Chroma tubing, packed with a 5
Lichrosorb RP-18 (Merck, Darmstadt, F.R.G.). The column was
packed using a Model 705 stirred-slurry column packer (Mi-
cromeritics Instruments Corporation, Norcross, GA 30093,
U.S.A.) and then mounted in a temperature-controlled oven. The
recorder was a type BD41 Model Kipp (Kipp and sons, Delft,
The Netherlands).
For the solvent precipitation of the serum proteins we used a mi-
crocentrifuge, Model Select-a-Fuge 24, obtained from the Allen
Medical Instrument Division, Bio-Dynamics Inc., Santa Ana, CA
U.S.A.
Reagents and Standards
All chemicals used were of reagent grade. Distilled water was
used throughout.
Mobile phose buffer: this is a degassed solution of 40 ml of aceto-
nitrile (Gold label, Aldrich, Beerse, Belgium) in 60 ml of phos-
phate buffer (pH 6.9).
Phosphate buffer: add 0.5 mol/1 KOH to a solution of 1.36g
KH2PO4 in 800 ml HaO until a pH of 6.9 is reached, and dilute to
1000ml with distilled H2O.
Drug Standards: phenobarbital, allylisobutylbarbital and pheny-
toin were obtained from Siegfried AG (Switzerland), primidone
and phenylethylmalonamide were a gift from ICI, Brüssels (Belgi-
um); ethosuximide from Parke Davis and Gq., Bornein (Belgi-
um); carbamazepine and carbamazepine-lO,ll-epoxide were a
gift from Ciba-Geigy» Brüssels (Belgium).
Procedure
Add 30 of acetonitrile containing 750 ng of allylisobutylbarbital
(äs an internal Standard) to 30 of serum or plasma in an Epperi-
dorf 1.5 ml polypropylene microtube. Vortex, mix the mixture for
10s, then centrifuge ät 8000 min"1 (5400g) for 5min. Inject
about 5 ] of the supernate directly onto the column and elute
with the mobile phase at a flow rate of 0.8 ml/min (pressure:
1000 psi) and a column temperature of 50 °C. With deteriorating
columns, however, a better Separation can be achieved at a flow
rate of 0.6 ml/min (pressure: 800 psi) arid a cpluriin temperature
of 30 °C. The UV absorption is registered at 208 nm at a sensitivl·
ty setting of 0.04 A füll scale. Concentrations of phenobarbital
higher than 25 mg/1 were measured at 0.1 A füll scale.
Results
We evaluated several Chromatographie cönditions
based on the procedures described by Soldifi etal.
(6) and Kabra et al. (8) using a 300 mm x 4.0 mm
i.d. RP-18 10 column. By extending the column
length to 600 mm, fifteen anticonvulsants may be se-
parated using the cönditions reported in the fprmer
method. A§ both the analysis time and the high pres-
sure made the method less applicable for routine
analysis, we decided to determine the optimal ana-
lytical variables for a simultaneous analysis of five
common anticonvulsants and two active metabolites
using the aforementioned 300 rnm colüöin.
Opt imum cönditions
The composition of the mobile phase, the pH of the
mobile phase and the temperature of the coliimn
were varied to obtain optimal Chromatographie cön-
ditions. The most satisfäctory Separation of phenyl-
ethylmalonamide, primidone, ethosuximide and
phenobarbital from serum components e. g. creati-
nine and uric acid was obtained at roöm temperäture
when the pH of the phosphate buffer componerit of
the eluent was äböut 6.9, and the ratio of the buffer
to acetonitrile was 60:40 by Volume.
Iricreäsing the temperature to 50 °C provided an
adequate Separation öf phenytoin and carbam-
azepine with acceptable loss of resolutibn between
ethosuximide and primidone. Lowering the tempef-
ature below 40 °C resulted not only in a loss of reso-
lution of carbamazepine and phenytoin but also in
longer retention times. The preferred temperature
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was therefore 50 °C. A.flow rate of 0.8 ml/min for
the mobile phase resulted in an analysis time of
12min at 50 °C (fig. 1).
Using this conditions we can inject 400 samples of
5 deproteinised serum without loss of resolution
or peak broadening.
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Fig. 1. Chromatogram of the serum used for the precision study
given in table l. The spiked serum contained per liter:
10 mg of phenylethylmalonamide (1), 12.3 mg of primi-
done (2), 40 mg of ethosuximide (3), 20 mg of phenobar-
bital (5), 3.8mg of carbamazepine-10,11-epoxide (6),
19.2 mg phenytoin (8), 7.6 mg of carbamazepine (9). Peak
7 represents the internal Standard. For this analysis the
serum was supplemented with 10 mg/1 4-hydroxy-pheny-
toin (4), an inactive metabolite accumulating in uraemic
patients.
UV-detection
A detector wavelength of 208 nm was chosen after
careful study of the UV-spectra of the anticonvul-
sants at their therapeutic and subtherapeutic concen-
trations (fig. 2). Although it has been reported that
the sensitivity of determination of carbamazepine-
10,11-epoxide is 1/15 of that of carbamazepine at
254 nm (1), this metabolite was easily detected in
the nanogram ränge at 208 nm; this was achieved
with an improved UV-detection, using ä variable
wavelength spectrophotometer, equipped with a
time constant and heat exchanger, which substantial-
ly reduce the instrumental noise.
For the 5 sample, the detection limit of the drugs
examined is less than l mg/1 (ränge 0.3 to 0.9 mg/1),
except for ethosuximide for which the detection limit
is 3 mg/1.
Quantitation
The chromatogram was quantitated by measuring
the ratio of drug to internal Standard, based on peak
height or peak area. Both methods were quite satis-
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Fig. 2. Ultra-violet spectra of some anticonvulsants and their
metabolites at therapeutic or subtherapeutic concentra-
tions.
(1) pKenylethylmalonamide 10 mg/1 (2) primidone
12.3 mg/1 (3) ethosuximide 40 mg/1 (4) phenobarbital
20.0 mg/1 (5) carbamazepine-10,11-epoxide 3.8 mg/1 (6)
phenytoin 19.2 mg/1 (7) carbamazepine 7.6 mg/1.
factory for this analysis. In every single nm a serum-
free Standard of anticonvulsants and metabolites is
run with an appropriate eontrol serum in order to
monitor retention times and to cälculate relative re-
sponse factors.
The investigation of linearity was carried out in the
ränge of 1—50 mg/1, except for ethosuximide
(1^200 mg/1). The resülts showed good linearity in
this ränge.
Precision
The precision of the method was assessed by repeat-
. ed analysis of pooled sera containing a Standard mix-
ture of the drügs and the active metabolites being
investigated. As shown in table l, within day preci-
sion varied between 2.3% and 6.8%, day-to-day
precision between 3.2% and 7.9%.
Recovery
The recovery from serum was checked by spiking a
drug-free serum with five different concentrations of
anticonvulsant drugs and active metabolites. Resülts
were expressed äs fractions of the peak heights ob-
tained by the direct injection of the serum-free
Standards. As shown in table 2, absolute recoveries
of the drugs ränge from 0.93 to 1.03, whereas abso-
lute recoveries of the active metabolites varied from
0.91 to 1.07.
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Tab. 1. Precision for measurement of anticonvulsant drugs in Interferences
plasma
c(mg/l)
Within day
n CV
Day to day
n CV
Phenylethyl-
malonamide 10
Primidone 12.3
Ethosuximide 40
Phenobarbital 20
Carbamazepine- 10,1 1-
epoxide 3.8
Phenytoin 19.2
Carbamazepine 7.6
10
10
10
10
10
10
10
6.8
5.2
2.9
2.3
4.5
3.7
4.1
15
15
15
15
15
15
15
7.9
6.2
3.9
3.2
5.2
4.4
5.4
Tab. 2. Recovery of anticonvulsants from plasma
Added Recovered Recovery
(mg/1) (rog/0 (fraction)
Phenylethylmalonamide
Primidone
Ethosuximide
Phenobarbital
Carbamazepine- 10,1 1-
epoxide
Phenytoin
Cärbamazepine
2.0
4.0
6.0
8.0
10.0
3.1
4.1
6.2
8.1
12.3
10.2
13.6
20.4
40.8
59.0
5.0
7.3
10.0
19.8
21.8
0.95
1.2
1.9
2.9
3.8
4.8
6.4
9.6
14.9
19.2
1.9
2.5
3.8
7.0
7.6
1.9
3.9
5.5
7.4
10.8
3.0
4.0
6.0
7.8
12.5
10
13.7
20.2
41.3
57.8
4.8
6.8
9.6
20
23
0.86
1.3
2.0
2.6
3.9
4.6
6.3
9.2
14.3
18.6
1.8
2.4
3.8
7.1
7.8
0.95
0.98
0.91
0.93
1.08
0.96
0.98
0.97
0.96
1.02
0.98 '
1.01
0.99
1.01
0.98
0.96
0.93
0.96
1.01
1.05
0.91
1.08
1.05
0.90
1.03
0.96
0.98
0.96
0.96
0.97
0.95
0.96
1.00
1.02
1.03
Potential interference by currently described drugs
was investigated by chromatographing each drug.
Table 3 lists the relative retention time of the cofii-
ponents tested. The retention time ,<pf the internal
Standard allylisobutylbarbital was assigned a value of
100.
Good practice in drug monitoring iiivolves the avail-
ability to the labpratory of complete Information
about the medication taken by the patient. As can be
seen from table 3 some co-elutions cannot be ex-
Tab. 3. Relative retention times (Internal: Standard = 100)
First serum component 3.4
Uric acid 40
Acetylosälicylic add 41
Hippuric acid 44
Amphetamine 48
Creatinine 49
Last serüm component 55
Acetaminophen 57
Cimetidine 58
Phenylethylmalonamide 61
Barbital 63
Primidone 64
Ethosuximide 66
Allobarbital 68
4-Hydroxyphenytoin 72
Antipyrine 74
Phenobarbital 76
Trimethadione 78
Alloisopropylbarbital 81
Ethylphenylhydantoin 83
Carbamazepine-10,ll-epoxide ' 87
Cyclobarbital 92
Aminopyrine 98
Phensuximide 102
Acetophenetidine 108
Paramethadione 113
Beclamide 125
Amobarbital 126
Phenytoin 127
Mephenytoin 129
Mephobarbital 131
Pentobarbital 132
Carbamazepine 135
Ethylphenacemide 140
Thiopental 146
Hexobarbital 150
Secobarbital 156
Clomethiazole 157
Nitrazepam 158
Methsuximide 164
Papaverine 166
Codeine 170
Theophylline 172
Clonazepam 174
Oxazepam 175
Cyheptamide 189
Chlordiazepoxide 208
Methaqualone 242
Diazepam · did not elute
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cluded. With the aid of this table it is possible (for
the user of this HPLC procedure) to identify possible
interfefences. Special attention must be paid to the
interference of antipyrine in the quantification of
phenobarbital. The chromatogram of metabolites
shows that doubling the column length and changing
the operating temperature can be used s final re-
finements in the quantification of the drugs.
Discussion
Soldin et al. (6) and Kabra et al. (8) described the
use of reversed-phase HPLC for the simultaneous
determination in serum of phenobarbital, phenytoin,
primidone, ethosuximide and carbamazepine. Later
Kabra et al. (9) extended their method to the analy-
sis of phenylethylmalonamide, mephenytoin and its
active metabolite 5-ethyl-5-phenylhydantoin. Final-
ly Soldin (11) reported the use of radial compression
columns.
In these and our procedure, the sera are deprotei-
nised by adding an equal amount of acetonitrile to
the samples, followed by centrifugation in polyprop-
ylene tubes at a relative high centrifugal force to ob-
tain a complete precipitation of serum proteins. In
order to extend the useful life of the column we
prefer to inject a small sample volume (5 μΐ) instead
of 20 μΐ (8,9).
In his first method Soldin et al. (6) described the use
of a mobile phase consisting of an equivolume mix-
ture of potassium phosphate buffer (pH = 8.0) and
acetonitrile, which resulted in a serious deterioration
of the column packing material due to the alkaline
pH of the eluent.
The mobile phase of their new System (11), consist-
ing of phosphate buffer (pH = 6.7) and acetonitrile
(52.5/47.5 by volume), guarantees a longer column
life, but in both methods the primidone metabolite
phenylethylmalonamide interferes with the analysis
of primidone, which results in falsely elevated levels
of primidone. The use of a pH 4.4 phosphate buffer,
however, which is proposed by Kabra et al. (8) ne-
cessitated the restriction of the ratio of acetonitrile/
phosphate buffer to about 20/80 parts by vol. in
order to obtain a good Separation between ethosux-
imide, primidone and phenylethylmalonamide. Fur-
thermore, using these conditions, a pressure of 11
MPa (1600 psi) had to be maintained, resulting in a
flow rate of 3.0 ml/min, in order to restrict the analy-
sis time to about 14 min at an Optimum column
temperature of 50 °C. To resolve also the active met-
abolite of carbamazepine, carbamazepine-10,11 -ep-
oxide, and to make the method more suitable for
routine analysis, we propose that the anticonvulsants
be eluted with a mobile phase consisting of acetoni-
trile/phosphate buffer (pH 6.9) (40/60 by vol) at a
flow-rate of 0.8 ml/min (1000 psi) and a column
tempefature of 50 °C; this requires only 12 min for
completion. Further we monitor the column effluent
at 208 nm rather than at 195 nm, not only because of
the absorption maxima of the anticonvulsants but al-
so to prolong the useful life of the UV-lamp of the
detector. Finally we propose that the 10 μηι small-
particle column material be replaced by 5 μπι parti-
cles to increase column efficiently.
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